Financial Ratios

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE1803.50-2.95 (-0.16 %)
PREV CLOSE ( ) 1806.45
OPEN PRICE ( ) 1801.75
BID PRICE (QTY) 1803.50 (3)
OFFER PRICE (QTY) 1803.80 (37)
VOLUME 25338
TODAY'S LOW / HIGH ( )1792.80 1809.85
52 WK LOW / HIGH ( )1547.25 1917.15
NSE1805.30-0.7 (-0.04 %)
PREV CLOSE( ) 1806.00
OPEN PRICE ( ) 1808.00
BID PRICE (QTY) 1805.30 (17)
OFFER PRICE (QTY) 1805.40 (149)
VOLUME 879700
TODAY'S LOW / HIGH( ) 1792.60 1809.90
52 WK LOW / HIGH ( )1548 1916.6
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)17.8511.917.05-0.423.51
   CEPS(Rs)23.0118.5813.725.218.66
   DPS(Rs)16.0013.5011.5010.007.50
   Book NAV/Share(Rs)101.4598.7698.98102.48112.28
   Tax Rate(%)14.8717.152.89132.581.54
Margin Ratios
   Core EBITDA Margin(%)28.4227.1330.8616.9814.18
   EBIT Margin(%)25.7520.8810.634.427.05
   Pre Tax Margin(%)21.8717.018.371.955.37
   PAT Margin (%)18.6214.108.12-0.645.29
   Cash Profit Margin (%)24.0021.9915.827.9513.06
Performance Ratios
   ROA(%)9.886.864.10-0.232.03
   ROE(%)17.8312.057.00-0.393.28
   ROCE(%)16.9212.817.282.193.46
   Asset Turnover(x)0.530.490.510.370.38
   Sales/Fixed Asset(x)1.251.131.190.951.32
   Working Capital/Sales(x)40.111.942.58-39.085.73
Efficiency Ratios
   Fixed Capital/Sales(x)0.800.890.841.050.76
   Receivable days162.92143.6599.70125.78146.18
   Inventory Days57.2166.7264.8379.2969.43
   Payable days184.71187.09175.92217.66220.03
Valuation Parameters
   PER(x)97.23136.03139.510.00170.21
   PCE(x)75.4287.2071.66175.6068.97
   Price/Book(x)17.1116.419.938.935.32
   Yield(%)0.920.831.171.091.26
   EV/Net Sales(x)18.5419.7011.6814.3610.64
   EV/Core EBITDA(x)59.5466.0036.0057.9061.31
   EV/EBIT(x)71.9994.36109.82322.06133.70
   EV/CE(x)12.0811.507.755.453.40
   M Cap / Sales18.1019.1811.3314.0810.16
Growth Ratio
   Net Sales Growth(%)13.46-2.5833.5310.4112.64
   Core EBITDA Growth(%)18.32-10.3574.6757.83-42.00
   EBIT Growth(%)39.9291.29218.47-38.12-69.32
   PAT Growth(%)49.8469.051790.89-111.87-73.77
   EPS Growth(%)49.8469.051791.07-111.87-73.77
Financial Stability Ratios
   Total Debt/Equity(x)0.450.470.320.200.26
   Current Ratio(x)1.033.361.970.961.28
   Quick Ratio(x)0.852.581.490.620.94
   Interest Cover(x)6.635.404.691.794.20
   Total Debt/Mcap(x)0.030.030.030.020.05

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.